Home›Trial›NCT02628067
🔬NCT02628067Phase 2ACTIVE NOT RECRUITING

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Study Summary

In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).

Conditions
Advanced CancerAnal CarcinomaAnal CancerBiliary CancerCholangiocarcinomaBile Duct CancerNeuroendocrine TumorCarcinoid TumorEndometrial CarcinomaEndometrial CancerCervical CarcinomaCervical CancerVulvar CarcinomaVulvar CancerSmall Cell Lung CarcinomaSmall Cell Lung Cancer (SCLC)MesotheliomaThyroid CarcinomaThyroid CancerSalivary Gland CarcinomaSalivary Gland CancerSalivary CancerParotid Gland CancerAdvanced Solid TumorsColorectal Carcinoma
Interventions / Drugs
pembrolizumabpembrolizumab
View on ClinicalTrials.gov ↗
Sponsor
MRK
Merck & Co
Oncology/Vaccines
F34/100
Study Details
Enrollment1609 participants
Primary Completion—
Lead SponsorMerck Sharp & Dohme LLC
Data Retrieved2026-04-11 02:55:36.204365+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.